Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IIITerminatedD-0926-2017

Drug recall · July 5, 2017

Gaviscon recall

Why: Superpotent Drug: high out-of-specification result for magnesium.

Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).

The recall

Product

Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distributed by: GlaxoSmithKline Consumer Healthcare, L.P., Moon Twp, PA 15108, UPC 3 0088-1175-47 8.

Lots / codes

Lot #: 5J69A, Exp 02/19; 6GF2A, 6GF3A, Exp 08/19

Quantity
2980 bottles
Company
Sanofi-Aventis U.S. LLC, Bridgewater, NJ
Distribution
Nationwide in the USA, Puerto Rico, and the United Kingdom.
Initiated
June 12, 2017 · Voluntary: Firm initiated
Classified
June 29, 2017
Reported
July 5, 2017
Ended
February 7, 2019
How notified
Letter

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.